Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s12471-013-0496-6) contains supplementary material, which is available to authorized users.
To assess current antithrombotic treatment strategies in the Netherlands in patients undergoing transcatheter aortic valve implantation (TAVI).
For every Dutch hospital performing TAVI (n = 14) an interventional cardiologist experienced in performing TAVI was interviewed concerning heparin, aspirin, thienopyridine and oral anticoagulation treatment in patients undergoing TAVI.
The response rate was 100 %. In every centre, a protocol for antithrombotic treatment after TAVI was available. Aspirin was prescribed in all centres, concomitant clopidogrel was prescribed 13 of the 14 centres. Duration of concomitant clopidogrel was 3 months in over two-thirds of cases. In 2 centres, duration of concomitant clopidogrel was based upon type of prosthesis: 6 months versus 3 months for supra-annular and intra-annular prostheses, respectively.
Leaning on a small basis of evidence and recommendations, the antithrombotic policy for patients undergoing TAVI is highly variable in the Netherlands. As a standardised regimen might further reduce haemorrhagic complications, large randomised clinical trials may help to establish the most appropriate approach.
ESM 1 (DOC 87 kb)12471_2013_496_MOESM1_ESM.doc
THV-Group. Dutch Guidelines for Transcatheter Heart Valve Intervention [Internet]. 2012. Available from: https://www.nvvc.nl/media/richtlijn/167/Guidelines%20THI%202012-DEF.pdf.
Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart. 2012;303095:1–6.
Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013 Jun 6.
Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013 Feb;12:1107–15.
- Antithrombotic therapy in patients undergoing TAVI: an overview of Dutch hospitals
V. J. Nijenhuis
P. R. Stella
B. R. G. Brueren
P. P. de Jaegere
P. den Heijer
S. H. Hofma
A. F. M. van den Heuvel
F. van der Kley
L. van Garsse
K. G. van Houwelingen
A. W. J. van’t Hof
J. M. ten Berg
- Bohn Stafleu van Loghum